Cervical screening with primary HPV testing can work in a vaccinated population: new evidence from Australia

Studies have shown that primary screening with HPV testing, when combined with various forms of triage, offers greater security than cytology, and at longer screening intervals (Tota & Ratnam ). Furthermore, it has been argued that, with the introduction of child HPV vaccination, there will have to be shift from cytology to HPV testing in primary cervical […]

Read More…

The efficacy of Gardasil nonavalent HPV vaccine

The best choice of HPV vaccine – Gardasil 4vHPV, Cervatrix 2vHPV or Gardasil 9vHPV – will no doubt vary from one country to another. But decisions regarding the relative cost-effectiveness and affordability of a particular vaccine depend upon estimates of its efficacy. As regards the most recent vaccine, Gardasil 9vHPV, Huh & Luxembourg (H&L) have […]

Read More…

What is the future of cervical screening in the era of HPV vaccination?

With the introduction of HPV child vaccination programmes, there will have to be a shift from cytology to HPV testing as the main technology involved in primary cervical screening, say the contributors to an on-coming special issue of Preventive Medicine (Tota & Ratnam I) (T&R). Why?  Well, first, because of the inevitable decline in the positive […]

Read More…

Where HPV vaccination loses the battle for public support: calculating the health implications for Japan

A recent brief contribution to The Lancet-Oncology (Tanaka & Ueda) uses predictions of the probable health outcomes of the suspension of the Japanese HPV vaccination programme to make the case for an urgent reassessment of the current policy.  This intervention is very timely.  The approved age for HPV vaccination for Japanese girls is a window of four years […]

Read More…

Prevention of anogenital cancers in women may be an additional benefit of HPV vaccination

Cervical cancer is evidently the most important, but by no means the only, health risk that vaccination against HPV aims to avert. The potential impact of vaccination on other cancers (not to mention genital warts) may also be a factor in estimating the cost benefit of achieving higher vaccination coverage, as well as determining priorities […]

Read More…

Mathematical models say: switching to HPV nonavalent vaccine brings cost benefits.

STI journal issues of nearly a decade ago, when HPV vaccination was a relatively new thing, hosted a discussion on the issue of which vaccine to choose. The choice at that time, readers will remember, was between GSK’s Cervarix 2vHPV and Merck’s Gardasil 4vHPV (Morris/STIs)*.  Now, the introduction of a third alternative, Gardasil (9vHPV), seems to […]

Read More…

Impressive declines in #HPV types amongst 14-24 yr olds in the US, despite poor vaccination coverage

Conclusive demonstration of cancer prevention benefits of HPV vaccination will only be possible in the relatively long term; good indicators of its probable effectiveness are, of course, already available. These include: reduced prevalence of the HPV types that have been vaccinated against; the decline in diagnoses of – or prescription for – genital warts; and […]

Read More…

Achieving HPV herd immunity cost-effectively. When does it make sense to allocate resources preferentially to boys?

Recent empirical studies of HPV vaccination have provided evidence that marginal vaccination costs increase with coverage.  Let us take into account – they argue – not just the vaccine price, but the cost of education and outreach programmes that would be needed so as to reach the yet unvaccinated population.  If we do so, we […]

Read More…

Population-based study concludes: HPV vaccination does not cause sexual disinhibition

HPV is known to be the cause of various types of cancer, including cervical cancer. Routine vaccination before the onset of sexual activity ought therefore to be effective in reducing the incidence of these cancers, and has been adopted by many countries.  The impact of such programmes will not be apparent for years; but the […]

Read More…

Heterosexual transmission of HPV to male oral tract via oral/genital route indicated by partner data

The UK Joint Committee for Vaccination and Immunization (JCVI) has not so far decided to extend HPV vaccination to boys, but this possibility remains under consideration (Public Health England Guidance on HPV 2014-15). The potential benefit of protecting males from face and neck cancer will be an important consideration, both in the UK and in […]

Read More…